10 Best Growth Stocks Under $30 to Buy Now
On June 12, Rick Rieder, BlackRock CIO, joined CNBC's 'Closing Bell' to discuss the overall picture for equity markets and the tech market.
Relmada Therapeutics Inc. (RLMD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squadron Capital Management William Blank | 7,350,000 | $50,862,000 | -14% | 15.78% |
| 2. | Spruce Street Capital Alex Rosen And Simon Basseyn | 6,391,328 | $44,227,990 | +3% | 8.68% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 4,763,158 | $32,961,053 | 0.05% | |
| 4. | OrbiMed Advisors Samuel Isaly | 3,631,195 | $25,127,869 | -24% | 0.47% |
| 5. | Millennium Management Israel Englander | 2,361,827 | $16,343,843 | -40% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.12 | 27,500 | $113,300.00 | 1,300,000 | 2025-12-15 | Filing | |
| $4.12 | 11,665 | $48,059.80 | 800,000 | 2025-12-15 | Filing | |
| $2.20 | 500,000 | $1,100,000.00 | 788,335 | 2025-11-05 | Filing | |
| $2.20 | 136,000 | $299,200.00 | 403,931 | 2025-11-05 | Filing | |
| $2.20 | 272,500 | $599,500.00 | 1,272,500 | 2025-11-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.32 | 4,068 | $74,525.76 | 88,774 | 2022-07-01 | Filing | |
| $18.45 | 8,848 | $163,245.60 | 92,842 | 2022-07-01 | Filing | |
| $18.48 | 839 | $15,504.72 | 101,690 | 2022-07-01 | Filing | |
| $19.01 | 10,698 | $203,368.98 | 88,774 | 2022-06-30 | Filing | |
| $19.37 | 5,314 | $102,932.18 | 99,472 | 2022-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,164,803 | $77,316,261 | 0.03% | |
| 2. | 7,426,780 | $51,393,319 | 0% | |
| 3. | 6,844,305 | $47,362,591 | 1.44% | |
| 4. | 4,460,210 | $30,864,653 | 0% | |
| 5. | 3,655,075 | $25,293,119 | 5.38% |
News See All
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026Relmada Therapeutics, Inc. misses on earnings expectations.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2025 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2025 Earnings Call Transcript November 13, 2025Relmada Therapeutics, Inc. misses on earnings expectations.
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company that develops innovative therapies for oncology and central nervous system disorders.
15 Best Biotech Penny Stocks to Invest in Right Now
Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC's "Closing Bell Overtime" in July on whether the biotech industry is ready for a breakthrough.
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study
Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology company developing therapies for central nervous system disorders and oncology.
13 Best Psychedelic Stocks to Invest in Now
Unlike drugs such as cocaine or marijuana, psychedelics create an “alternate reality” by altering feelings, thoughts, and energy levels.
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Relmada Therapeutics Second Quarter 2025 Earnings Conference Call.
Hedge Fund Resource Center